Key result
Extended dual antiplatelet therapy after percutaneous coronary intervention in patients with peripheral arterial disease did not significantly reduce MACCE compared to non-extended therapy (OR 0.76).
Meta-Analysis (n=895)
Odds Ratio: 0.76 (95% CI 0.37–1.57)
Absolute Event Rate: 12.8% vs 15.5%
p-value: p=0.46
Extended DAPT does not reduce MACCE after PCI in PAD; challenges routine extension and leaves stent thrombosis benefit open for larger trials.
Background: Patients with peripheral arterial disease (PAD) undergoing percutaneous coronary intervention (PCI) are at elevated risk of ischemic and bleeding events. However, the optimal duration of dual antiplatelet therapy (DAPT) after PCI in patients with PAD remains unclear. Methods: A systematic literature search was performed through June 2017 using PubMed, EMBASE and Cochrane databases with the following key terms: "dual antiplatelet therapy", "P2Y12 inhibitor", "myocardial infarction", "percutaneous coronary intervention", "stent", "peripheral arterial disease", and "ankle-brachial index". The analysis was restricted to randomized trials published in English in patients with PAD receiving extended DAPT (> 12-month) after PCI. Overall analysis was performed using Review Manager 5.3 with the Mantel-Haenszel method. Results: Two randomized controlled trials involving 895 patients were included in this review. Compared to the placebo group, there was no statistical significance in the occurrence of major adverse cardiovascular and cerebrovascular events (MACCE) in patients receiving extended DAPT (odds ratio (OR) 0.76, 95% confidence interval (CI) 0.37 - 1.57; P = 0.46). The results were associated with substantial heterogeneity (I 2 = 71%, P = 0.07). Extended DAPT was not significantly associated with increased moderate/severe bleeding events (OR 1.63, 95% CI 0.84 - 3.18; P = 0.15; I 2 = 0%, P = 0.59). The extended DAPT was associated with 82% relative risk reduction in the events of definite/probably stent thrombosis. Conclusions: Among patients with PAD, extended DAPT after PCI resulted in a non-significant difference in ischemic and bleeding events compared to placebo, respectively. The routine use of extended DAPT in this cohort should be carefully evaluated. Cardiol Res. 2018;9(3):137-143 doi: https://doi.org/10.14740/cr719w
No takes yet. Share an insight, caveat, or question.
Ling et al. (2018) conducted a meta-analysis in Peripheral arterial disease (PAD) undergoing percutaneous coronary intervention (PCI) (n=895). Extended duration dual antiplatelet therapy (DAPT) vs. Non-extended DAPT (≤ 12-month) was evaluated on Major adverse cardiovascular and cerebrovascular events (MACCE) (OR 0.76, 95% CI 0.37 - 1.57, p=0.46). Extended dual antiplatelet therapy after percutaneous coronary intervention in patients with peripheral arterial disease did not significantly reduce MACCE compared to non-extended therapy (OR 0.76).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: